About Platelet-activating factor acetylhydrolase 2, cytoplasmic
Platelet-activating factor acetylhydrolase 2, cytoplasmic (PAFAH2) is a protein
from Homo sapiens identified by UniProt accession
Q99487, 392 residues long.
MolForge cross-references it against 0 known binders and
25 disease associations.
Target properties
| Protein name | Platelet-activating factor acetylhydrolase 2, cytoplasmic |
| UniProt accession | Q99487 |
| Gene | PAFAH2 |
| Organism | Homo sapiens |
| Length | 392 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (25)
Diseases linked to this target (Open Targets).
- urate measurement · score 0.17
- bone density · score 0.17
- Pallister-Hall syndrome · score 0.06
- pediatric hepatocellular carcinoma · score 0.04
- neonatal hemochromatosis · score 0.03
- nonpapillary renal cell carcinoma · score 0.03
- pulmonary arterial hypertension · score 0.02
- Acute kidney injury · score 0.01
- acute kidney failure · score 0.00
- neoplasm · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q99487-F1 | alphafold | PREDICTED | 91.04 | — |
Amino-acid sequence (392 residues)
MGVNQSVGFP PVTGPHLVGC GDVMEGQNLQ GSFFRLFYPC QKAEETMEQP LWIPRYEYCT GLAEYLQFNK RCGGLLFNLA VGSCRLPVSW NGPFKTKDSG YPLIIFSHGL GAFRTLYSAF CMELASRGFV VAVPEHRDRS AATTYFCKQA PEENQPTNES LQEEWIPFRR VEEGEKEFHV RNPQVHQRVS ECLRVLKILQ EVTAGQTVFN ILPGGLDLMT LKGNIDMSRV AVMGHSFGGA TAILALAKET QFRCAVALDA WMFPLERDFY PKARGPVFFI NTEKFQTMES VNLMKKICAQ HEQSRIITVL GSVHRSQTDF AFVTGNLIGK FFSTETRGSL DPYEGQEVMV RAMLAFLQKH LDLKEDYNQW NNLIEGIGPS LTPGAPHHLS SL
Explore Platelet-activating factor acetylhydrolase 2, cytoplasmic with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets